Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. develops, markets and sells health and wellness products through a secure telemedicine platform under the MangoRx and PeachesRx brands. Company news commonly covers telehealth programs for erectile dysfunction, hair growth, hormone replacement therapy and weight management, including prescription access and fulfillment through pharmacy partners when medically appropriate.
Recurring updates also include product and intellectual-property developments such as MGX-0024, an antiviral animal feed and drinking water additive technology, as well as capital actions, platform operations and legal matters involving technology vendors. The company’s releases often connect its wellness brands, digital consultation model and eCommerce infrastructure to new treatment categories and operating initiatives.
MangoRx (NASDAQ: MGRX) has launched its oral Semaglutide weight loss treatment, branded as 'Slim', on its website. This GLP-1 receptor agonist is formulated as an oral dissolvable tablet (ODT) compounded with Vitamin B6, offering a convenient option for weight management. The company aims to capitalize on the growing GLP-1 market, projected to reach $157.5 billion by 2035.
MangoRx is pricing 'Slim' at $299 per month, positioning it as an affordable and accessible treatment. The company believes this launch will drive revenue growth and expand its market share in the weight loss category. MangoRx's telemedicine platform is expected to provide customers with a seamless and secure experience, further enhancing its ability to serve the growing weight loss market.
MangoRx (NASDAQ: MGRX) reported significant financial growth for the first half of 2024. The company's shareholders' equity surged by 1,685% to $13.8 million, largely due to the acquisition of a global patent portfolio for respiratory illness technology. Gross revenues increased by 55.92% to $377,258, with gross profit up 50.48% to $217,190 compared to the same period in 2023.
The company, focused on men's health and wellness products, anticipates further growth in the second half of 2024. This expectation is supported by ongoing product development, market expansion efforts, and the recent launch of a DEA-approved telemedicine operating system. MangoRx is also preparing to launch new weight loss products featuring Semaglutide and Tirzepatide, as well as a hormone therapy product for low testosterone treatment.
MangoRx (NASDAQ: MGRX) has received a Certificate of Grant in India for its respiratory illness and preventive care technology patent. The patent, valid until March 16, 2040, covers a proprietary formulation designed to combat infections including colds, respiratory diseases, and orally transmitted infections like HPV. This follows MangoRx's acquisition of Intramont Technologies' global patent portfolio on April 24, 2024.
The technology uses an orally available solution containing GALALCOOL®️, zinc protoporphyrin IX, and select tannins to inhibit various pathogens. MangoRx and Intramont have initiated clinical trials in India to demonstrate the formulation's efficacy in preventing respiratory illnesses, with results expected later this quarter. The company is also considering expanding trials to address avian influenza concerns.
MangoRx (NASDAQ: MGRX) has successfully migrated to a DEA-approved telemedicine platform, marking a significant advancement in its capabilities. This new system allows MangoRx's third-party doctor network to prescribe controlled substances, including Prime by MangoRx, an Oral Testosterone Replacement Therapy. The platform has accelerated the company's timeline for introducing new product lines, particularly the Slim and Trim weight loss products featuring Semaglutide and Tirzepatide in oral dissolvable tablets.
The company expects to launch these products before the end of Q3, capitalizing on the high demand for GLP-1 weight loss treatments. MangoRx has also unveiled a redesigned website with improved UI/UX, optimized for enhanced customer workflows. The HIPAA-compliant system ensures regulatory compliance and data security, setting a new benchmark for excellence in telemedicine.
MangoRx (NASDAQ:MGRX), a men's health telemedicine company, has received its first Request for Proposal (RFP) from the International Society of Frontier Life Sciences and Technology (ISFLST) for a new male enhancement product targeting the Asian market. The product will be manufactured in the USA using GMP-compliant facilities. A pilot program is planned for 50 retail locations in China, with potential expansion to 5,000 locations.
The company's participation in a Beijing exhibit was successful, leading to new distribution partnerships and media coverage. MangoRx plans to expand its presence with exhibits in Shanxi Province, Hangzhou, and Beijing. Additionally, the company's existing products, Mango and Grow, are under review for regulatory approval in Asian markets.
MangoRx (NASDAQ: MGRX) has initiated efficacy studies on its patented respiratory illness prevention technology. The studies, pre-funded and expected to conclude in early Q3, will be conducted in collaboration with Vipragen Biosciences and IntraMont Technologies. The technology aims to reduce the incidence of respiratory illnesses, including H1N1 variants, Avian Flu, common cold, and Coronavirus.
The composition being tested contains a select tannin (enhanced polyphenol) and zinc gluconate. Previous research at Moscow State University showed a 93% decrease in active virus compared to the control group. The product is anticipated to be available as a lozenge or toothpaste, targeting the global influenza market valued at $8.28 billion in 2023.
Mangoceuticals (NASDAQ: MGRX) CEO Jacob Cohen was recently featured on Benzinga All-Access, discussing the company's strategic direction and future plans. Cohen highlighted MangoRx's focus on developing and marketing men's health products in areas such as erectile dysfunction, hair growth, weight loss, and hormone replacement therapies.
During the interview, Cohen emphasized the company's commitment to innovation and excellence in the health and wellness industry. He also discussed recent developments, expanding product offerings, and plans for global expansion, particularly in emerging markets. Cohen expressed optimism about the significant growth opportunities within the health and wellness sector and MangoRx's position to capitalize on these opportunities.
MangoRx (NASDAQ: MGRX) has secured DEA approval for its proprietary HIPAA-compliant operating system via Surescripts, positioning the company at the forefront of the direct-to-consumer telemedicine market. This authorization allows MangoRx to prescribe controlled medications, including hormone replacement therapies, through the nation's leading health information network.
The approval is expected to drive significant growth by enabling the company to expand its offerings and hyperscale operations. MangoRx's new operating system, developed over nearly a year, aims to revolutionize patient management with features like seamless doctor visits, prescription auto-refills, and personalized healthcare solutions. The company anticipates exponential growth in its subscriber base following this milestone.
MangoRx has appointed Dr. Douglas Christianson, N.D. as Director of Medical Research and Product Innovation. Dr. Christianson will drive new product development, conduct market research, and analyze innovative healthcare treatments for men's health, including erectile dysfunction, hair growth, weight loss, and hormone replacement therapies. He will develop and certify custom compound formulations and medical protocols, and collaborate with nationwide doctors for onboarding and training. Dr. Christianson, a specialist in male optimization therapies and regenerative medicine, brings extensive experience and insight into current market trends and progressive medicine. His expertise will help MangoRx expand its product offerings and stay ahead of competitors.
MangoRx (NASDAQ: MGRX) has announced a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) to expand its presence in China, Asia Pacific, and Latin America (excluding Mexico). This collaboration aims to enhance the visibility and adoption of MangoRx's men's health products, including erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, in these rapidly growing markets. ISFLST will leverage its network in the US, China, and South Korea to introduce MangoRx's products. CEO Jacob Cohen highlighted the substantial market opportunity, citing an estimated 400 million males aged 35 and above in China. Marketing activities have already begun in Beijing and Hangzhou, with further plans for South Korea and Southeast Asia.